Antibody-drug Conjugates-A Tutorial Review. Molecules. 2021;26. 16. Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736–42. 17. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et...
Antibody-drug Conjugates-A Tutorial Review. Molecules. 2021;26(10). Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. Article CAS PubMed PubMed Central Google Scholar Lee ...
Antibody drug conjugates (ADCs) are a unique therapy that combines the direct tumor targeting capability of monoclonal antibodies together with the potency of cytotoxic drugs [11]. Briefly, ADCs are composed of three distinct parts: a tumor-targeting monoclonal antibody (mAb) that specifically binds ...
, 20. This publication will provide a comprehensive SAR of antibody–siRNA conjugates, including optimal linker selection, points of conjugation on the antibody and siRNA, bioconjugation strategies to link an antibody and siRNA oligonucleotide, and the impact of siRNA oligonucleotide-to-antibody ratios ...
Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to ta
review mainly focuses on the chemistry, structure, mechanism of action, and role of antibody–drug conjugates in triple-negative breast cancer. Datopotecan Deruxtecan (Dato-DXd) is a new-generation ADC showing encouraging results for TNBC. In this review, we have also emphasized TROP-2-directed...
pharmaceutics Review Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy Joshua Hurwitz 1,2,† , Lucy Roxana Haggstrom 3,† and Elgene Lim 1,2,* 1 St. Vincent's Clinical School, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2053, ...
1. Introduction Antibody–drug conjugates (ADCs) have gained great attention in oncology research and clinical studies as a novel strategy for targeted drug delivery. ADC development began in the early 1960s [1,2]. Knowledge accumulated over the past two decades, including a number of ...